Q2 2026 Oncoinvent ASA Earnings Call Transcript
Key Points
- Phase 2 trial in ovarian cancer is on track with 55 patients recruited, crossing the halfway mark and achieving the two best recruitment quarters in Q1 and Q2 2026.
- Strengthened IP position with a new patent in China and presented phase 1 data at ESGO, with abstracts accepted at ESMO and EANM.
- Cash position of 109 million NOK is expected to fund operations into 2027, with operating cash burn slightly below budget despite increased recruitment activity.
- Manufacturing de-risked by in-house pilot plant, with plans for redundancy via a CDMO outside Europe and scaling projects on track for phase 3 readiness.
- FDA fast track designation in ovarian cancer supports potential for accelerated approval and priority review, with phase 3 preparations underway including regulatory discussions and site rollover from phase 2.
- Strong safety profile and one-and-done treatment design expected to drive swift adoption if approved, addressing high unmet medical need in peritoneal metastases.
- Phase 2 interim results are not expected until late 2027, with the main nine-month follow-up readout also late in 2027, leaving significant uncertainty.
- Phase 3 trial will require a significantly larger patient population and is subject to regulatory discussions, with no exact design or timeline confirmed.
- Manufacturing hold for two weeks in Q3 2026 due to scheduled maintenance could temporarily impact recruitment pace.
- Partnership agreements are not imminent, with no target date disclosed, and the company acknowledges it cannot provide details on ongoing discussions.
- Cash burn is expected to continue at current levels, and the company may need additional funding or partnerships to support phase 3 and commercialization.
- Expansion into other indications like colorectal and gastric cancer is deprioritized due to financial constraints, limiting near-term pipeline diversification.
Ladies and gentlemen, welcome to Oncoin Events' first half year presentation. My name is Oystein Saug. I am the CEO and with me today I have CFO Ramsey Amry.
I'd like to remind you that you can ask questions online that we will attempt to answer towards the end of the presentation.
So we have a short and sweet presentation for you today. We'll go through the highlights, give you a clinical update, financial update and a bit of outlook.
And so far in 2026, development has been good for Onco Invent.
Now, clearly the most important value driver in the company for us today is the execution of the phase two trial in ovarian cancer.
And we included four additional sites into that trial during the first quarters.
So now we have 55 patients. Recruited into that trial. So that trial is on track.
We also strengthened our IP position in China with a new patent.
And on the scientific front, we had lots of activity in first quarters.
First of all, we presented our phase one
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
